SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-039674
Filing Date
2024-04-02
Accepted
2024-04-01 20:12:13
Documents
13
Period of Report
2024-03-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.03: Bankruptcy or Receivership
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K acor-20240331.htm   iXBRL 8-K 66353
2 EX-99.1 acor-ex99_1.htm EX-99.1 24429
3 GRAPHIC img123754176_0.jpg GRAPHIC 13300
  Complete submission text file 0000950170-24-039674.txt   235400

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT acor-20240331.xsd EX-101.SCH 24851
16 EXTRACTED XBRL INSTANCE DOCUMENT acor-20240331_htm.xml XML 4711
Mailing Address TWO BLUE HILL PLAZA PEARL RIVER NY 10965
Business Address TWO BLUE HILL PLAZA PEARL RIVER NY 10965 914-347-4300
Acorda Therapeutics, Inc. (Filer) CIK: 0001008848 (see all company filings)

IRS No.: 133831168 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-31938 | Film No.: 24811836
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)